Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNTA NASDAQ:INCR NASDAQ:PASG NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$3.810.0%$3.89$2.74▼$7.28$69.68M0.5926,367 shs2,376 shsINCRInterCure$1.54-0.3%$1.53$1.17▼$2.43$70.18M1.1835,598 shs32,648 shsPASGPassage Bio$7.44+29.8%$7.56$5.12▼$26.60$17.88M1.6777,648 shs453,082 shsPMVPPMV Pharmaceuticals$1.41-2.1%$1.10$0.81▼$1.82$74.81M1.49323,922 shs285,871 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science+1.86%+0.90%+24.19%-5.32%-12.07%INCRInterCure0.00%+2.67%+1.99%+4.05%-34.47%PASGPassage Bio-0.87%-0.69%-18.52%-11.02%-65.42%PMVPPMV Pharmaceuticals+6.67%+8.27%+24.14%+38.46%-11.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNTAGenenta Science2.7337 of 5 stars3.53.00.00.03.81.70.0INCRInterCure0.661 of 5 stars0.03.00.00.03.30.00.6PASGPassage Bio3.3936 of 5 stars3.52.00.00.03.92.51.3PMVPPMV Pharmaceuticals3.167 of 5 stars3.53.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNTAGenenta Science 3.00Buy$25.00556.34% UpsideINCRInterCure 0.00N/AN/AN/APASGPassage Bio 3.00Buy$150.001,916.13% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50290.07% UpsideCurrent Analyst Ratings BreakdownLatest PASG, INCR, PMVP, and GNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AINCRInterCure$64.55MN/AN/AN/A$2.36 per shareN/APASGPassage BioN/AN/AN/AN/A$19.84 per shareN/APMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AINCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)PASGPassage Bio-$64.77M-$20.40N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)Latest PASG, INCR, PMVP, and GNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PASGPassage Bio-$0.20N/AN/AN/AN/AN/A8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A5/13/2025Q1 2025PASGPassage Bio-$4.80-$5.00-$0.20-$0.25N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNTAGenenta ScienceN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNTAGenenta ScienceN/A6.896.89INCRInterCure0.341.731.18PASGPassage BioN/A3.743.74PMVPPMV PharmaceuticalsN/A16.7516.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNTAGenenta Science15.13%INCRInterCure8.34%PASGPassage Bio53.48%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipGNTAGenenta Science28.99%INCRInterCure0.24%PASGPassage Bio5.00%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableINCRInterCure350N/AN/AOptionablePASGPassage Bio1303.12 million2.96 millionOptionablePMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionablePASG, INCR, PMVP, and GNTA HeadlinesRecent News About These CompaniesRobert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockJuly 4, 2025 | insidertrades.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) COO Robert Ticktin Sells 23,151 SharesJuly 3, 2025 | marketbeat.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $35,048.90 in StockJuly 3, 2025 | marketbeat.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO David Henry Mack Sells 58,411 SharesJuly 3, 2025 | marketbeat.comPmv Pharmaceuticals Inc (PMVP) - Investing.comJuly 3, 2025 | investing.comPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comQPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comAHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 21, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBest Prime Day Ever? Here Are the Prime Winners Riding the WaveBy Thomas Hughes | July 14, 2025View Best Prime Day Ever? Here Are the Prime Winners Riding the Wave4 Major Stocks Raise 2025 Guidance, Analyst Targets RiseBy Leo Miller | July 23, 2025View 4 Major Stocks Raise 2025 Guidance, Analyst Targets RiseKinder Morgan: At the Hotspot of the Natural Gas RevolutionBy Thomas Hughes | July 21, 2025View Kinder Morgan: At the Hotspot of the Natural Gas RevolutionThe 4 Dividend Stocks Smart Money Is Grabbing Right NowBy Thomas Hughes | July 24, 2025View The 4 Dividend Stocks Smart Money Is Grabbing Right NowGameStop: Clarity Brings Renewed Confusion for Meme StockBy Thomas Hughes | July 22, 2025View GameStop: Clarity Brings Renewed Confusion for Meme StockPASG, INCR, PMVP, and GNTA Company DescriptionsGenenta Science NASDAQ:GNTA$3.82 +0.00 (+0.13%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.InterCure NASDAQ:INCR$1.54 -0.01 (-0.32%) Closing price 03:57 PM EasternExtended Trading$1.56 +0.03 (+1.63%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Passage Bio NASDAQ:PASG$7.44 +1.71 (+29.84%) Closing price 04:00 PM EasternExtended Trading$7.28 -0.17 (-2.22%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.PMV Pharmaceuticals NASDAQ:PMVP$1.41 -0.03 (-2.08%) Closing price 04:00 PM EasternExtended Trading$1.41 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
